Please assess the completion status of the following clinical trial:

Trial Title: Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age≥18 years~* Confirmed G1, G2 or G4 HCV infection~* Plasma HCV-RNA ≥1000 IU/mL~* No history of HCV treatment of any kind~* Willingness to use a birth control method (hormonal or intrauterine device for women, condoms for men), starting before HCV treatment initiation and continued until 4months (women) and 7 months (men) after end of treatment.~* Weight ≥40 kg and ≤125 kg~For patients infected with HIV :~* Confirmed HIV-1 infection~* Stable HIV treatment for at least 8 weeks with two NRTIs (tenofovir or abacavir, and lamivudine or emtricitabine) and a third agent (raltegravir, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, efavirenz, nevirapine)~* Current CD4+ lymphocytes count ≥100/mm3~* Current plasma HIV-1 RNA \<200 copies/mL~Exclusion Criteria:~For each patient:~* Cirrhosis classified Child-Pugh B or C~* Co-infection by the Hepatitis B virus~* Pregnant or breastfeeding ongoing~* History of transplantation of organs or tissues~* Progressive Cancer, including hepatocellular carcinoma~* Epilepsy~* Sickle Cell Disease~* A history of myocardial infarction or other severe heart disease~* Excessive consumption of alcohol or drug users, in the absence of substitution by methadone, a stable weaning for more than three months should be required~* Ongoing Participation in another clinical trial~* Contraindications to the Sofosbuvir as defined in the Summary of Product Characteristics~* At least one of the following laboratory abnormalities:~Haemoglobin \<10 g / 100 ml (woman) \<11 g / 100 ml (man) Platelet count \<50,000 / mm3 polymorphonuclear neutrophils rate \<750 / mm3 Creatinine clearance \<50ml / min~For patients infected with HIV:~* Severe opportunistic infections in the last 6 months~* Poor adherence to antiretroviral treatment history~* Use of antiretroviral drugs other than those permitted in the test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+Ribavirin (Type: EXPERIMENTAL): Sofosbuvir 400mg QD (Sovaldi®) + Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
- Sofosbuvir+Ledipasvir (Type: EXPERIMENTAL): Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)

Based on this trial design, predict the completion outcome and termination type (if applicable).